Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Broad Approach Required for Histoplasmosis Diagnosis

By LabMedica International staff writers
Posted on 06 Sep 2011
An immunoassay has been used to improve the diagnosis of histoplasmosis, which is often diagnosed by a combining antigen and antibody testing, as well as culture and pathology. More...


The sensitivity of the MVista Histoplasma antigen enzyme immunoassay (EIA) has been evaluated in disseminated histoplasmosis in patients with Acquired Immunodeficiency Syndrome (AIDS) and in the “epidemic” form of acute pneumonia.

Scientist at Indiana University (Indianapolis, IN, USA) collected serum and urine samples from 218 patients with histoplasmosis; 158 with disseminated disease and 60 with pulmonary infection, and 229 controls. The patients evaluated came from eight medical centers during the period from November 2004 through December 2007, and they were tested for Histoplasma and/or Blastomyces antigen at a commercial laboratory. The MVista Histoplasma antigen EIA was modified to permit quantification below the level of 0.6 ng/mL by incorporating 0.2 ng/mL and 0.4 ng/mL calibrators and removing those of ≥19 ng/mL. Serum specimens were treated with 4% EDTA at 104 °C before testing.

In the group with disseminated histoplasmosis, the rate of antigenuria, the presence of the specific antigen in the urine, was 91.8%. Sensitivity for the presence of the specific antigen in the serum, antigenemia, was similar. Culture findings were positive in 74.2% of cases, and similar rates were seen with pathology (76.3%) and antibody testing (75.0%). The sensitivity of the test in pulmonary cases varied, as antigenuria was positive in 83.3% of acute cases, in 87.5% of chronic cases, but in only 30.4% of subacute cases. Conversely, antibody results were positive in 66.7%, 95.1%, and 83.3% of those three categories, respectively. The control group included 30 subjects with blastomycosis, and the histoplasmosis tests were 90% cross-reactive in this group. However, the histoplasmosis antigen-enzyme immunoassay was 99% specific when tested in healthy subjects and those with nonfungal infections.

MVista Histoplasma antigen quantative sandwich EIA is a product of MiraVista Diagnostics (Indianapolis, IN, USA) where the laboratory analysis was carried out. Chadi A. Hage, MD, the senior author of the study, and his colleagues concluded that their study supports a broad approach, using antigen testing of urine and serum samples, antibody testing, culture, and pathology for diagnosis of disseminated or pulmonary histoplasmosis. The study was published online on August 2, 2011, in the journal Clinical Infectious Diseases.

Related Links:

Indiana University
MiraVista Diagnostics




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.